LSD Archives - Green Market Report

Dave HodesMay 2, 2022


“Psychedemia” is a mix of “psychedelic” and “academia”—meaning the integration of psychedelics into academia—and is a term coined by LSD research pioneer Humphry Osmond in 1957. 

It has been used since 2012 as the title for a grassroots collaborative psychedelics conference organized to “foster novel contributions to this burgeoning field,” and to “consider data from new research with an open mind.” 

The three-day psychedemia conference in 2012 was organized by the University of Pennsylvania, the Penn Medicine Neuroscience Center, the Perelman School of Medicine, the Graduate and Professional Student Assembly, the School of Arts and Sciences Student Government, and several other departments was a grand gesture ten years ago to not only raise the awareness of psychedelics but give the whole industry a shot in the arm. 

It represented a sort of full-circle path of academia for psychedelics after academia abandoned psychedelics when Harvard University psychology professor Timothy Leary derailed the industry in the 60s after doing experiments with psilocybin and LSD that “lacked scientific rigor”

Now academia is reclaiming psychedelics and putting more university brainpower into it than ever before.

The psychedemia conference is still going on, with the next one scheduled in August 2022, as a partnership with the newly founded Center for Psychedelic Drug Research and Education at Ohio State University. It will be presented on the campus.

But academia-inspired conferences and the founding of university-related psychedelics studies centers are just the tip of the iceberg in the huge rush by academia to embrace and better understand psychedelics. 

Masters Degrees

Universities are creating master’s degree level psychedelics classes, attracting world-class scientists to help find novel psychedelics therapeutics, and pushing to create a broader and deeper intellectual base for psychedelics study and research that is just gaining traction.

Here’s a quick look at five developments of note among the reported 100-plus U.S. universities researching psychedelics: 

  1. The Stanford University School of Medicine began an introduction to psychedelics as a speaker series in 2018 and is now an official course at the school, “PSYC 215: Introduction to Psychedelic Medicine.”
  2. In January 2021, the Center for Psychedelic Psychotherapy and Trauma Research was launched at Mount Sinai Health System with the James J. Peters Department of Veterans Affairs Medical center, to examine the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms. Mount Sinai Health System is New York City’s largest academic medical system, made up of eight hospitals, a medical school, and a network of ambulatory practices throughout the greater New York region.
  3. In July, 2021, Tryp Therapeutics (OTC: TRYPF) partnered with the University of Michigan to work on part of a series of upcoming studies performed with the Chronic Pain and Fatigue Research Center and the Center for Consciousness Science in the Department of Anesthesiology at the University of Michigan. The series is designed to explore the relationship between a psilocybin-induced increase in neurophysiological complexity and indices of pain in a preclinical model for chronic central pain.
  4. In August, 2021, the University of Wisconsin–Madison opened the doors to its Transdisciplinary Center for Research in Psychoactive Substances to support research and educational activities about psychedelic drugs and related compounds. The center also supports the university’s master’s degree program, “Psychoactive Pharmaceutical Investigation.”
  5. In March, 2022, the Yale School of Medicine announced that physician-scientists at three major U.S. medical schools will collaborate to develop a curriculum to train psychiatrists in the practice of psychedelic medicine. The project, a collaboration between Yale School of Medicine, Johns Hopkins University School of Medicine, and New York University Grossman School of Medicine, will be funded by a $1 million grant provided by a group of donors, according to a press release.

Brian Pace, a scholar at Ohio State University who teaches psychedelics studies at the university, and is one of the organizers of the 2022 Psychedemia conference to be held at Ohio State, told Open Foundation, a Netherlands non-profit think tank, that the new-agey, cultish stuff they see around psychedelics now, with tuning your chakras and merging souls or whatever, is their fault. “That’s an abdication of the responsibility to investigate interesting questions and to chase down data: to find out how things work,” Pace said. “So where we are now is a very timid and late re-entry to the subject, more so for education than research. Psychedelic research didn’t end when the universities and governments abandoned it. It continued in the underground. The role of the university courses on psychedelics is to identify and evaluate high-quality information on the topic. We have a lot of catching up to do and I think that should be done with humility.”

StaffApril 19, 2022


While most people in the cannabis industry are gearing up for the high holiday of April, 20 or 420, our good friends in the psychedelic industry have their own day of celebration. It’s called Bicycle Day and it falls on April 19. The history is that on April 19, 1943, Albert Hofmann, the Swiss father of psychedelic medicine, dropped lysergic acid diethylamide (LSD) at 4:20 pm, interestingly enough, and went on a bike ride, becoming the first human to trip on LSD.

According to Wikipedia, “Hofmann’s condition rapidly deteriorated as he struggled with feelings of anxiety, alternating in his beliefs that the next-door neighbor was a malevolent witch, that he was going insane, and that the LSD had poisoned him. When the house doctor arrived, however, he could detect no physical abnormalities, save for a pair of incredibly dilated pupils. Hofmann was reassured, and soon his terror began to give way to a sense of good fortune and enjoyment, as he later wrote…”

“… Little by little I could begin to enjoy the unprecedented colors and plays of shapes that persisted behind my closed eyes. Kaleidoscopic, fantastic images surged in on me, alternating, variegated, opening and then closing themselves in circles and spirals, exploding in colored fountains, rearranging and hybridizing themselves in constant flux. It was particularly remarkable how every acoustic perception, such as the sound of a door handle or a passing automobile, became transformed into optical perceptions. Every sound generated a vividly changing image, with its own consistent form and color”

Hofmann realized he had made a significant discovery: a psychoactive substance with extraordinary potency, capable of causing significant shifts of consciousness in incredibly low doses. Hofmann viewed the drug as a powerful psychiatric tool; because of its intense and introspective nature, he couldn’t imagine anyone using it recreationally.

The celebration of Bicycle Day originated in DeKalb, Illinois, in 1985, when Thomas B. Roberts, then a Professor at Northern Illinois University, invented the name “Bicycle Day” when he founded the first celebration at his home. Several years later, he sent an announcement made by one of his students to friends and Internet lists, thus propagating the idea and the celebration. While this holiday isn’t as widespread as 420, a series of events honoring the day is beginning to happen.


Bicycle Day Psychedelic Pseder

Darkhei Rephua and Students for Sensible Drug Policy present: Bicycle Day Psychedelic Pseder at Floating Lotus

An evening of song, stories, and psychedelic celebration of Pesach (Passover), holistic liberation, and the launch of

In partnership with NYC Psychedelic Society.

Doors open at 7:00pm. Dinner begins at 7:30 PM sharp. Party begins at 9:00 PM.

Dinner will be vegetarian and kosher for Passover.


Debra BorchardtDecember 15, 2020


Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) entered into an agreement with Canaccord Genuity Corp. to purchase, on a bought deal basis an aggregate of 11,364,000 units of the company at a price of C$4.40 per unit for gross proceeds of C$50 million. the company said the net proceeds will be used for investment in Project Lucy, Albert (the company’s digital medicine division), additional microdosing research and development, Project Layla (18-MC) as well as general working capital.

MindMed also announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of lysergic acid diethylamide (LSD) assisted therapy for anxiety disorder. This FDA meeting is an important milestone for the company and provides regulatory clarity and confidence as MindMed advances its lead clinical development program in the U.S. The psychedelic drug company also said it plans to open the IND with the FDA in August 2021, with a Phase 2b clinical trial evaluating experiential doses of LSD in an anxiety disorder.

MindMed Co-Founder & Co-CEO J.R. Rahn said “The FDA is one of the most impactful organizations for regulated drug development globally. We look forward to working through the FDA pathway on psychedelic-assisted therapies in strict compliance with their proven drug development guidelines and commencing our Phase 2b trial for Project Lucy in 2021.”

While Project Lucy focuses on LSD, Project Layla has been tagged as an addiction treatment program evaluating the ibogaine derivative 18-MC. The preliminary data from the Phase 1 Multiple Ascending Dose (MAD) and Single Ascending Dose (SAD) study has shown that the drug is safe and well-tolerated at the doses tested to date and that no serious side effects have been reported.

MindMed’s clinical team and 18-MC’s Medical Director, Dr. Judy Ashworth, have decided to continue dose escalation in the study to gather higher dosing data. The company has said that once that additional data has been reviewed, MindMed will directly thereafter initiate the Phase 2a proof of concept study. A meeting with the FDA has been confirmed to continue discussions regarding the 18-MC clinical development plan.

Latest Offering

In addition to raising C$50 million, each unit shall consist of one subordinate voting share and one-half of one Subordinate Voting Share purchase warrant of the company. The statement said that each Warrant shall be exercisable to acquire one Subordinate Voting Share at an exercise price of C$5.75 per Subordinate Voting Share for a period of 3 years from the closing of the Offering, subject to a Warrant acceleration right exercisable by the company if the daily volume-weighted average trading price of the Company’s Subordinate Voting Shares on the NEO Exchange is greater than C$9.00 per Subordinate Voting Share for the preceding 5 consecutive trading days.

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 21 hours

New Colorado Rules: More Packaging Mandates, But Also Supply Chain Flexibility

@GreenMarketRpt – 22 hours

Michigan Gov. Whitmer Makes Marijuana Top Cop’s Role Permanent

@GreenMarketRpt – 1 day

Michigan Man Who Halted Some NY Licensing Suing Los Angeles

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.